Pharmalitet

For only the third time, an Indian drug maker is seeking to win a compulsory license in order to make and sell a generic version of a brand-name medicine. And the effort is likely to be closely watched as the global pharmaceutical industry looks for signs that the Indian government will alter its approach toward protecting patent rights.


http://blogs.wsj.com/pharmalot/2015/07/09/will-india-issue-a-compulsory-license-for-an-astrazeneca-diabetes-pill/?mod=WSJBlog